Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (21-30 of 269) with videos related to

Pageof 27
Sort By:
Journal of Crohn'S & Colitis|November 10, 2021
A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's DiseaseGeert D'Haens, Silvio Danese, Martin Davies, et al.
Journal of Crohn'S & Colitis|January 7, 2021
Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound IndexSteven Bots, Kim Nylund, Mark Löwenberg, et al.
Journal of Patient-Reported Outcomes|October 9, 2018
Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label studyMary Kaye Willian, Geert D'Haens, Aaron Yarlas, et al.
The American Journal of Gastroenterology|May 9, 2012
Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitisGeert D'Haens, William J Sandborn, Karen Barrett, et al.
Inflammatory Bowel Diseases|August 18, 2009
Clinical guidelines for the management of pouchitisDarrell S Pardi, Geert D'Haens, Bo Shen, et al.
Current Gastroenterology Reports|November 12, 2009
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)Marc Ferrante, Geert D'Haens, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|August 13, 2019
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic ReviewJean-Frédéric Colombel, Geert D'haens, Wan-Ju Lee, et al.
Drugs|November 12, 2024
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical ConsiderationsOle Haagen Nielsen, Alexander Hammerhøj, Mark Andrew Ainsworth, et al.
Journal of Crohn'S & Colitis|April 3, 2012
What do changes in inflammatory bowel disease management mean for our patients?Subrata Ghosh, Geert D'Haens, Brian G Feagan, et al.
Acta Gastro-Enterologica Belgica|July 11, 2007
Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot studyEduard Louis, Jacques Boverie, Olivier Dewit, et al.
Pageof 27

Showing results (21-30 of 269) with videos related to

Sort By:
Pageof 27
Journal of Crohn'S & Colitis|November 10, 2021
A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's DiseaseGeert D'Haens, Silvio Danese, Martin Davies, et al.
Journal of Crohn'S & Colitis|January 7, 2021
Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound IndexSteven Bots, Kim Nylund, Mark Löwenberg, et al.
Journal of Patient-Reported Outcomes|October 9, 2018
Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label studyMary Kaye Willian, Geert D'Haens, Aaron Yarlas, et al.
The American Journal of Gastroenterology|May 9, 2012
Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitisGeert D'Haens, William J Sandborn, Karen Barrett, et al.
Inflammatory Bowel Diseases|August 18, 2009
Clinical guidelines for the management of pouchitisDarrell S Pardi, Geert D'Haens, Bo Shen, et al.
Current Gastroenterology Reports|November 12, 2009
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)Marc Ferrante, Geert D'Haens, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|August 13, 2019
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic ReviewJean-Frédéric Colombel, Geert D'haens, Wan-Ju Lee, et al.
Drugs|November 12, 2024
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical ConsiderationsOle Haagen Nielsen, Alexander Hammerhøj, Mark Andrew Ainsworth, et al.
Journal of Crohn'S & Colitis|April 3, 2012
What do changes in inflammatory bowel disease management mean for our patients?Subrata Ghosh, Geert D'Haens, Brian G Feagan, et al.
Acta Gastro-Enterologica Belgica|July 11, 2007
Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot studyEduard Louis, Jacques Boverie, Olivier Dewit, et al.
Pageof 27